Highest-materiality recent filing
Paridiprubart reduced adjusted 28-day mortality to 24% from 33% (27% relative risk reduction; p<0.001) in full 278-patient population.
Edesa reports FY2025 net loss $7.2M; Phase 3 paridiprubart meets endpoints
Net loss $7.2M ($1.27/share) vs $6.2M ($1.93/share) prior year; OpEx $7.9M.
Paridiprubart + SOC reduced 28-day mortality to 39% vs 52% placebo (n=104; p<0.001): 13% absolute improvement, 25% relative risk reduction.
Project completion extended to December 31, 2028 (from December 31, 2025); agreement expiration extended to later of Dec 2045 or last repayment.
Edesa Biotech files prospectus supplement for up to $4.0M ATM offering through H.C. Wainwright
ATM offering for up to $4,006,544 of common shares through H.C. Wainwright.
Edesa Biotech reports Q2 net loss of $1.6M; advances vitiligo drug EB06 to Phase 2
Net loss of $1.6M ($0.30/share) vs $1.9M ($0.58) in prior-year Q2; operating expenses fell to $1.6M.
Edesa Biotech reports Q1 FY2025 net loss of $1.6M; raises $15M in private placement
Net loss of $1.6M ($0.48/share) compared to $1.7M ($0.54/share) in prior year quarter.
Edesa Biotech announces $15M private placement led by Velan Capital; appoints David Liu to board
Gross proceeds of $15M from sale of Series B-1 convertible preferred shares ($10K each) and 3.47M common shares at $1.92/share.
Edesa Biotech FY2024 net loss $6.2M ($1.93/sh); cash $1.0M, negative working capital
Net loss $6.2M ($1.93/sh) vs $8.4M ($2.93/sh) prior year; operating expenses down 24% to $7.0M.
Edesa Biotech enters $5M securities purchase agreement with CEO; $1.54M immediate investment
CEO-affiliated entity invests $1,540,819 for 150 Series A-1 Preferred Shares ($10K stated value) and warrants at $3.445 conversion/exercise price.
Edesa Biotech reports Q3 net loss $1.7M; ARDS drug selected for U.S. government study
Net loss of $1.7M ($0.52/shr) vs $2.0M ($0.68/shr) a year ago; nine-month loss $5.2M ($1.64/shr).
BARDA selects Edesa's paridiprubart for U.S. government-funded Phase 2 ARDS trial
Paridiprubart (EB05) chosen by BARDA for a randomized, double-blind, placebo-controlled Phase 2 platform trial in all-cause ARDS.
the Company appointed Peter J. Weiler to serve as the Company’s Chief Financial Officer, effective May 1, 2025
Stephen Lemieux, Chief Financial Officer of Edesa Biotech, Inc. (the “Company”), notified the Company of his intention to resign from his position and responsibilities as Chief Financial Officer, effective May 1, 2025, to pursue another professional opportunity.
the Company appointed David Liu, the Lead Investor Nominee, to serve on the Board of Directors
Max materiality 0.85 · Median 0.60 · Most common event other_material